Benefits offered by microbial biomanufacturing, such as low
production costs and faster development timelines, have led many innovators to
adopt these platforms for next generation biologics, offering lucrative
opportunities for CMOs / CDMOs
Roots Analysis is pleased to announce
the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.”
The
report features an extensive study of the current market landscape and future
opportunities associated with the microbial contract biomanufacturing market. It
features a detailed analysis of key drivers and trends related to this evolving
domain. In addition to other elements, the study includes:
§ A
detailed review of the current landscape of companies offering contract
manufacturing services.
§ Elaborate
profiles of key players that specialize in offering services for contract
biomanufacturing.
§ A competitiveness
analysis, highlighting key players engaged in microbial based contract
manufacturing, featuring insightful pictorial summaries and representations.
§ An
analysis of the partnerships and expansions that have been established in this
domain, in the recent past.
§ A competitiveness
analysis, highlighting key players engaged in microbial based contract
manufacturing, featuring insightful pictorial summaries and representations.
§ A
detailed proprietary 2×2 representation to assess the current market scenario
§ An
analysis of the initiatives of big biopharma players engaged in this domain.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
§
Type of Product
§
API
§
FDF
§ Type
of Biologic
§ Proteins
§ Enzymes
§ Growth
Hormones
§ Antibody
based Drugs
§ Others
(plasmid DNA, probiotics, microbiome-based biologics)
§
Type of Microbial Expression System
§ Bacteria
§ Yeast
§ Others
(Algae and fungi)
§ Scale
of Operation
§ Commercial
§ Preclinical
/ Clinical
§ Type
of End User
§ Small
Companies
§ Mid-sized
Companies
§ Large
/ Very Large Companies
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia
Pacific
§ Middle
East and North Africa
§ Latin
America
Transcripts of interviews held with the
following senior level representatives of stakeholder companies
§ Gaurav Kaushik (Chief
Executive Officer and Managing Director, Meteoric
Biopharmaceuticals)
§ Debbie Pinkston (Vice
President, Sales and Business Development, List Biological Laboratories)
§ Andrea Conforto
(Sales and Marketing, Bioservices Director, Olon)
§ Max Rossetto (General
Manager, Business Development, Luina
Bio)
§ Rob van Dijk
(Business Development Manager, WACKER
Biotech)
Key
companies covered in the report
§ AGC
Biologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ Northway
Biotechpharma
§ Ology
Bioservices
§ Porton
Biopharma
§ Stelis
Biopharma
For additional
details, please visit
https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Drug
Repurposing Service Providers Market, 2020 – 2030
2. Antibody
Discovery Services and Platforms Market (3rd Edition), 2020-2030
3. Live
Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on
Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030
Contact:
Gaurav Chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
